文献速递先天性心脏病外科心外重症与机械循环支持

Fontan患者系统性心室辅助装置支持:ACTION报告

Systemic ventricular assist device support in Fontan patients: A report by ACTION.
PubMed 文献 · J Heart Lung Transplant · 2021-01-19

本研究回顾性分析ACTION注册网中45例植入心室辅助装置(VAD)的Fontan患者,平均年龄10岁,76%为移植前桥接。最常见装置为HeartWare HVAD(56%),67%发生不良事件(神经事件25%)。1年时移植率69.5%,持续VAD支持9.2%,死亡率21.3%,VAD可降低部分患者Fontan及心室舒张末压。

要点

  • VAD可作为Fontan终末期心衰患者等待心脏移植的有效桥接。
  • 植入后1年移植率69.5%,死亡率21.3%,不良事件常见。
  • 部分患者VAD可降低Fontan及心室舒张末压。

核心结论

  • VAD能有效支持等待心脏移植的终末期Fontan衰竭患者。

研究设计与样本

  • 回顾性研究,纳入Advanced Cardiac Therapies Improving Outcomes Network中45例植入VAD的Fontan患者。

主要发现

  • 平均年龄10岁(四分位距4.5-18),30%为女性。
  • 69%为形态学右心室,83%中重度以上心室功能障碍,65%中重度以上房室瓣反流。
  • 76%为移植前桥接,56%为Interagency Registry for Mechanically Assisted Circulatory Support Profile 2。
  • 最常用装置为Medtronic HeartWare HVAD(56%),13例带装置出院,67%发生不良事件,神经事件最常见(25%)。
  • 1年时移植率69.5%,持续VAD支持9.2%,死亡21.3%。

临床怎么用

  • 对于终末期Fontan衰竭等待移植的患者,可考虑VAD作为桥接治疗。
  • 需警惕高不良事件风险,尤其是神经事件。

局限性

  • 回顾性研究,样本量有限(45例)。
  • 需进一步识别预测VAD favorable反应的临床和生理特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The size of the Fontan population with end-stage heart failure is growing. In this population, heart transplantation has been the only option. This study sought to investigate the efficacy of ventricular assist device (VAD) support in Fontan patients. METHODS: We conducted a retrospective study of Fontan patients in the Advanced Cardiac Therapies Improving Outcomes Network. We evaluated patient characteristics, and the clinical and physiologic outcomes after VAD implantation. RESULTS: We identified 45 Fontan patients implanted with VAD. The average age of patients was 10 years (interquartile range: 4.5-18) and 30% were female. The majority had a morphologic right ventricle (69%), moderate or greater ventricular dysfunction (83%), and moderate or greater atrioventricular valve regurgitation (65%). The majority of implants were as a bridge to transplantation (76%), and the majority of patients were Interagency Registry for Mechanically Assisted Circulatory Support Profile 2 (56%). The most commonly employed device was the Medtronic HeartWare HVAD (56%). A total of 13 patients were discharged on device support, and 67% of patients experienced adverse events, the most common of which were neurologic (25%). At 1 year after device implantation, the rate of transplantation was 69.5%, 9.2% of patients continued to be VAD supported, and 21.3% of patients had died. Hemodynamically, VAD was effective in decreasing both Fontan and ventricular end-diastolic pressures in some individuals. CONCLUSIONS: VAD is effective in supporting patients with end-stage Fontan failure awaiting heart transplantation. Future research should focus on identifying clinical and physiologic characteristics predictive of a favorable response to VAD support.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Cedars A, Kutty S, Danford D, et al. Systemic ventricular assist device support in Fontan patients: A report by ACTION. J Heart Lung Transplant. 2021. PMID: 33642140. doi:10.1016/j.healun.2021.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。